Discovery of Novel UV-Filters with Favorable Safety Profiles in the 5-Arylideneimidazolidine-2,4-dione Derivatives Group

Justyna Popiół, Agnieszka Gunia-Krzyżak, Kamil Piska, Dorota Żelaszczyk, Paulina Koczurkiewicz, Karolina Słoczyńska, Katarzyna Wójcik-Pszczoła, Anna Krupa, Agata Kryczyk-Poprawa, Ewa Żesławska, Wojciech Nitek, Paweł Żmudzki, Henryk Marona, Elżbieta Pękala



Figure S1. The distribution of the angle values between the planes of hydantoin and aromatic rings in crystal structures containing a 5-benzylidenehydantoin (hyd), 5-benzylidene-2-thiohydantoin (S-hyd) or 5-benzylidene-2-selenohydantoin (Se-hyd) fragment retrieved from the CSD.



Figure S2. The overlap of hydantoin rings of **3b** (carbon atoms in grey) and **4g** (carbon atoms in green). The disordered fragment of **3b** is depicted only for major occupancy (**A**).

| | D-H…A | H…A (Å) | D…A (Å) | D-H-A (°) | Symmetry codes |
|----|-------------|---------|----------|-----------|---------------------------------|
| 3b | C8-H8A…O4 | 2.56 | 3.519(2) | 163 | -x + 1, -y + 2, -z + 2 |
| | C8-H8B…O4 | 2.64 | 3.400(2) | 134 | x, $-y + 2$, $z + \frac{1}{2}$ |
| | C9-H9A…O6A | 2.52 | 3.415(5) | 152 | x, y + 1, z |
| | C10-H10A…O2 | 2.29 | 3.130(2) | 142 | -x + 1/2, -y + 3/2, -z + 2 |
| | C14-H14…O1 | 2.76 | 3.354(1) | 121 | -x + 1, -y + 2, -z + 2 |
| | C16-H16…O1 | 2.63 | 3.383(2) | 137 | -x + 1, -y + 2, -z + 2 |
| | C21-H21B…O4 | 2.54 | 3.495(2) | 165 | x, y + 1, z |
| 4g | C6-H6A…O7 | 2.64 | 3.328(2) | 127 | −x + 1/2, y−1, −z |
| | C6-H6B…O1 | 2.59 | 3.399(2) | 139 | −x + 1/2, y, −z |
| | C13-H13C…O6 | 2.54 | 3.470(2) | 160 | $-x, y + 1/2, -z + \frac{1}{2}$ |
| | C14-H14…O4 | 2.22 | 2.965(2) | 134 | -x + 1/2, -y + 3/2, z |
| | C16-H16…O4 | 1.68 | 2.586(2) | 158 | -x + 1/2, -y + 3/2, z |
| | C19-H19-O2 | 2.49 | 3.425(2) | 168 | −x + 1/2, y + 1/2, −z |
| | C23-H23C…O5 | 2.65 | 3.310(2) | 125 | x + 1/2, -y + 2, z |

Table S1. Parameters of intermolecular interactions in the crystal structures of 3b and 4g



Figure S3. UV-absorption spectra of tested compounds and reference UV filters obtained in methanolic solutions (for **2a–2e**, **3a–3e**, octocrylene and EHMC at 50 μ M, for **4f–4h** and avobenzone at 25 μ M).

| Compd | λ_{\max} pre- | λ _{max} post- | % of initial | | |
|-----------|-----------------------|------------------------|--------------|--|--|
| | irradiation | irradiation | AUC post- | | |
| | | | irradiation | | |
| 1e | 341 | 346 | 95.38 | | |
| 2a | 316 | 317 | 70.45 | | |
| 2b | 334 | 341 | 95.67 | | |
| 2c | 336 | 344 | 96.89 | | |
| 2d | 349 | 354 | 100.96 | | |
| 2e | 344 | 351 | 97.8 | | |
| 3a | 295 | 301 | 122.34 | | |
| 3b | 318 | 326 | 114.39 | | |
| 3c | 321 | 329 | 119.42 | | |
| 3d | 333 | 342 | 111.55 | | |
| 3e | 329 | 340 | 129.32 | | |
| 4f | 354 | 354 | 59.12 | | |
| 4g | 379 | 378 | 80.15 | | |
| 4h | 370 | 370 | 98.55 | | |
| 4-MBC | 299 | 303 | 87.76 | | |
| EHMC | 309 | 307 | 63.26 | | |

Table S2. UV absorption changes after 1h irradiation at 500 W/m^2 of methanol solution of tested compounds and reference UV-filters.



Figure S4. UV absorption spectra of tested compounds and EHMC obtained pre-irradiation and 1 hour after irradiation with solar light simulator conducted at 500 W/m² in 25 μ M (**4g**) or 50 μ M (**2d**, **3b**, EHMC) methanol solutions.



Figure S5. The chromatograms and mass spectra of methanol solutions of compounds **3b** and **4g** preirradiation (**A**) and 1 hour after irradiation (**B**) with solar light simulator conducted at 500 W/m².

| Positive wells per microplate | | | | | | | | | | | |
|-------------------------------|---------------|-------------|---------|-------------|-----|-------------|------|-------------|------|-------------|-----|
| | | S. typh | imuriun | n | | | | | | E. coli | |
| | | TA98 | | TA100 | | TA1535 | | TA1537 | | WP2 | |
| | | - S9 | +S9 | - S9 | +S9 | - S9 | +S9 | - S9 | +S9 | - S9 | +S9 |
| Compound | Conc. (mM) | FIB* | | | | | | | | | |
| 4g | 0.1 | 0.5 | 0.3 | 1.1 | 0.7 | 0.3 | 0.3 | 0.3 | 1.4 | 0.3 | 0.6 |
| | 0.2 | 0.9 | 0.4 | 0.3 | 0.5 | 1.4 | 0.7 | 1.7 | 1.1 | 1.3 | 1.0 |
| | 0.5 | 0.2 | 0.6 | 0.6 | 0.5 | 0.6 | 0.3 | 0.5 | 0.8 | 1.3 | 0.7 |
| | PC** | 25.3 | 12.6 | 4.3 | 3.1 | 40.0 | 16.5 | 48.0 | 38.3 | 25.7 | 4.0 |
| 3b | 0.1 | 0.9 | 0.2 | 1.1 | 0.7 | 0.8 | 0.5 | 0.3 | 1.1 | 0.3 | 0.7 |
| | 0.2 | 0.2 | 0.4 | 0.8 | 0.6 | 0.6 | 0.1 | 0.3 | 1.1 | 0.7 | 0.6 |
| | 0.5 | 0.9 | 0.3 | 0.7 | 0.6 | 1.7 | 0.1 | 0.3 | 0.3 | 0.3 | 0.4 |
| | PC** | 25.3 | 12.6 | 4.3 | 3.1 | 40.0 | 16.5 | 48.0 | 38.3 | 25.7 | 4.0 |

Table S3. Mutagenic activity of compounds 4g and 3b tested with the Ames assay.

*FIB–fold induction over baseline (baseline = mean zero-dose control + 1 SD); SD–standard deviation **Positive controls: 2-Nitrofluorene (2-NF) at 2 μg/mL (TA98, –S9); 4-Nitroquinoline-*N*-oxide (4-NQO) at 0.1 μg/mL (TA100, –S9); N4-Aminocytidine (N4-ACT) at 100 μg/mL (TA1535, –S9); 9-Aminoacridine (9-AAc) at 15 μg/mL (TA1537, –S9); 4-NQO at 2 μg/mL (*E.coli uvrA*[pKM101], –S9); 2-Aminoanthracene (2-AA) at 0.5 μg/mL (TA98, +S9); 2-AA at 1.25 μg/mL (TA100, +S9); 9-AA at 2.5 μg/mL (TA1535 and TA1537, +S9); 2-Aminofluorene (2-AF) at 400 μg/mL (*E.coli uvrA*[pKM101], +S9).